by demo | Feb 17, 2021 | News, Press Release
GAINESVILLE, FL, USA, February 18, 2021 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced two additions to its...
by demo | Sep 23, 2020 | News, Press Release
Recognized as Early Stage Company with Ground-breaking TechnologyWinning Buzz of BIO gives us an additional boost going into BIO Investor Forum Digital where we will present this opportunity to potential new investors”— Helena CowleyGAINESVILLE, FL, USA, September 23,...
by demo | Sep 10, 2020 | News, Press Release
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Using a Proprietary Orally Administered Oxalate Decarboxylase (OxDC)GAINESVILLE, FLA, USA, September 10, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage...
by demo | Jul 9, 2020 | News, Press Release
GAINESVILLE, FL, USA, July 9, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced three additions to its...
by demo | Feb 18, 2020 | Events
Oxidien Pharmaceuticals have been accepted to present at Venture Summit West organized by YoungStartup Ventures, the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of...
